GlaxoSmithKline Pharmaceuticals Limited GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited

GLAXO

주식 순위 #3640
GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise,... GlaxoSmithKline Pharmaceuticals Limited, an India-based healthcare enterprise, engages in the research, development, production, and global distribution of pharmaceutical drugs and vaccines. Its extensive product range encompasses both prescription and over-the-counter medications addressing diverse therapeutic areas such as anti-infectives, respiratory ailments, dermatology, nutritional deficiencies, gastrointestinal issues, and rare conditions. The company additionally provides consumer healthcare solutions. Prominent brands within its portfolio include Augmentin, Calpol, Ceftum, Eltroxin, Neosporin, Betnovate, Infanrix Hexa, Synflorix, and Boostrix, among numerous others. Founded in 1924 and headquartered in Mumbai, India, the company adopted its current name in 2001, having previously operated as SmithKline Beecham Pharmaceuticals India Ltd.
주가
$27.73
시가총액
$4.70B
변동 (1일)
0.71%
변동 (1년)
-11.52%
국가
IN
거래 GlaxoSmithKline Pharmaceuticals Limited (GLAXO)

카테고리

Healthcare
GlaxoSmithKline Pharmaceuticals Limited (GLAXO)의 수익
Jun 2026 기준 수익 TTM: $159.96M
GlaxoSmithKline Pharmaceuticals Limited의 최신 재무 보고서에 따르면 회사의 현재 수익은 $159.96M입니다. 2024년에 회사는 $97.88M의 수익을 올렸으며 이는 2023년의 수익 $101.78M과 감소입니다. 이 페이지에 표시된 수익은 이자 및 세금 공제 전 수익으로, 즉 EBIT입니다.
GlaxoSmithKline Pharmaceuticals Limited의 수익 기록 (2004 ~ 2026)
연말 수익
연도 수익 변화
2026 (TTM) $159.96M 8.59%
2025 $147.31M 50.49%
2024 $97.88M -3.82%
2023 $101.78M -0.83%
2022 $102.63M 65.48%
2021 $62.02M 52.81%
2020 $40.59M -58.72%
2019 $98.31M 18.54%
2018 $82.93M 5.21%
2017 $78.83M -9.71%
2016 $87.30M -9.89%
2015 $96.88M -0.90%
2013 $97.77M -35.64%
2012 $151.90M -13.05%
2011 $174.69M -10.43%
2010 $195.02M 19.11%
2009 $163.74M 13.31%
2008 $144.51M -9.37%
2007 $159.46M 24.82%
2006 $127.75M 17.87%
2005 $108.38M 10.05%
2004 $98.49M 0.00%
유사 기업 또는 경쟁사의 수익
회사 수익 수익 차이 국가
$33.60B 20,902.13%
US
$17.74B 10,988.20%
US
$8.70B 5,338.14%
US
$5.95B 3,618.36%
US
$21.39B 13,270.79%
CH